EA028008B1 - Составы ингибитора lfa-1 - Google Patents

Составы ингибитора lfa-1 Download PDF

Info

Publication number
EA028008B1
EA028008B1 EA201591180A EA201591180A EA028008B1 EA 028008 B1 EA028008 B1 EA 028008B1 EA 201591180 A EA201591180 A EA 201591180A EA 201591180 A EA201591180 A EA 201591180A EA 028008 B1 EA028008 B1 EA 028008B1
Authority
EA
Eurasian Patent Office
Prior art keywords
approximately
formula
compound
compositions
compounds
Prior art date
Application number
EA201591180A
Other languages
English (en)
Russian (ru)
Other versions
EA201591180A1 (ru
Inventor
Мэри Ньюман
Уилльям Ханке
Original Assignee
Саркоуд Байосайенс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA028008(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Саркоуд Байосайенс Инк. filed Critical Саркоуд Байосайенс Инк.
Publication of EA201591180A1 publication Critical patent/EA201591180A1/ru
Publication of EA028008B1 publication Critical patent/EA028008B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EA201591180A 2012-12-19 2013-12-18 Составы ингибитора lfa-1 EA028008B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US201361758147P 2013-01-29 2013-01-29
PCT/US2013/076041 WO2014100135A1 (en) 2012-12-19 2013-12-18 Lfa-1 inhibitor formulations

Publications (2)

Publication Number Publication Date
EA201591180A1 EA201591180A1 (ru) 2015-12-30
EA028008B1 true EA028008B1 (ru) 2017-09-29

Family

ID=50979140

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201591180A EA028008B1 (ru) 2012-12-19 2013-12-18 Составы ингибитора lfa-1
EA201791321A EA201791321A1 (ru) 2012-12-19 2013-12-18 Составы ингибитора lfa-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201791321A EA201791321A1 (ru) 2012-12-19 2013-12-18 Составы ингибитора lfa-1

Country Status (20)

Country Link
US (2) US11058677B2 (enExample)
EP (2) EP2934510B1 (enExample)
JP (1) JP6373867B2 (enExample)
KR (1) KR101891144B1 (enExample)
CN (1) CN104955453B (enExample)
AU (1) AU2013361579B2 (enExample)
BR (1) BR112015014367B1 (enExample)
CA (1) CA2894170C (enExample)
DK (1) DK2934510T3 (enExample)
EA (2) EA028008B1 (enExample)
ES (1) ES2846724T3 (enExample)
HU (1) HUE052299T2 (enExample)
IL (1) IL239490B (enExample)
MX (2) MX391620B (enExample)
NZ (1) NZ708821A (enExample)
PL (1) PL2934510T3 (enExample)
PT (1) PT2934510T (enExample)
SI (1) SI2934510T1 (enExample)
WO (1) WO2014100135A1 (enExample)
ZA (2) ZA201504404B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
EP3955926A4 (en) * 2019-04-18 2022-11-30 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation
KR20230110516A (ko) * 2020-10-21 2023-07-24 아주라 오프탈믹스 엘티디 눈 장애의 치료를 위한 화합물 및 방법
CN116211796A (zh) * 2022-12-30 2023-06-06 新领先(重庆)医药科技有限公司 一种立他司特滴眼液及其制备方法
KR20240109779A (ko) * 2023-01-05 2024-07-12 주식회사 종근당 리피테그라스트와 토코페롤을 함유하는 건성안 예방 또는 치료용 약제학적 조성물
KR20250033790A (ko) 2023-09-01 2025-03-10 주식회사 와이에스생명과학 리피테그라스트 함유 점안 조성물
WO2025093739A1 (en) 2023-11-02 2025-05-08 Novaliq Gmbh Semifluorinated alkane compositions comprising lifitegrast
WO2025104294A1 (en) * 2023-11-17 2025-05-22 Bausch + Lomb Ireland Limited Semifluorinated alkane small molecule lfa-1 antagonist combination compositions for treatment of ocular disorders
CN117771174B (zh) * 2023-12-29 2025-07-29 鲁南贝特制药有限公司 一种立他司特滴眼液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
US20090298869A1 (en) * 2008-04-15 2009-12-03 John Burnier Crystalline pharmaceutical and methods of preparation and use thereof
US20120123162A1 (en) * 2009-06-29 2012-05-17 Sk Chemicals Co., Ltd Transdermal composition comprising tolterodine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
JP3631490B2 (ja) * 1992-05-13 2005-03-23 ノバルティス ファーマ株式会社 シクロスポリン含有眼科用組成物
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) * 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
JP5794721B2 (ja) * 2005-05-17 2015-10-14 サーコード バイオサイエンス インコーポレイテッド 眼障害の治療のための組成物および方法
EP1901708B1 (en) * 2005-07-08 2013-09-11 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
JP2011521896A (ja) 2008-04-15 2011-07-28 サーコード コーポレイション 免疫関連障害に対する局部治療に使用するための局所ｌｆａ−１アンタゴニスト
WO2010033800A2 (en) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
CN102176920B (zh) * 2008-11-17 2013-09-18 莱拉制药用品私营有限责任公司 姜黄素及其用于治疗眼科疾病的方法
EP2441453B1 (en) * 2009-06-10 2014-11-26 Mitotech SA Pharmaceutical composition for use in medical and veterinary ophthalmology
BR112012012387A2 (pt) * 2009-11-23 2019-09-24 Allergan Inc 7-[3,5-di-hidroxi-5-fenil-pent-1-enil)-ciclopentil]-n-etil-hept-5-enamida (bimatoprost) na forma cristalina ii, métodos para a preparação e métodos de utilização da mesma
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
US20130317058A1 (en) * 2011-02-18 2013-11-28 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
US20130005708A1 (en) * 2011-06-29 2013-01-03 Lalwani Dinusha N Histamine antagonist treatment of inflammatory skin disorders
ES2978927T3 (es) * 2012-03-29 2024-09-23 Epion Therapeutics Inc Soluciones de tratamiento ocular, dispositivos de administración y métodos de aumento de la administración
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090257957A1 (en) * 2008-04-15 2009-10-15 John Burnier Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
US20090298869A1 (en) * 2008-04-15 2009-12-03 John Burnier Crystalline pharmaceutical and methods of preparation and use thereof
US20120123162A1 (en) * 2009-06-29 2012-05-17 Sk Chemicals Co., Ltd Transdermal composition comprising tolterodine

Also Published As

Publication number Publication date
BR112015014367B1 (pt) 2022-11-22
KR20150100763A (ko) 2015-09-02
ES2846724T3 (es) 2021-07-29
MX2019012375A (es) 2020-01-20
ZA201608069B (en) 2017-11-29
US20220000859A1 (en) 2022-01-06
CN104955453A (zh) 2015-09-30
EP2934510A4 (en) 2016-08-17
HK1214963A1 (en) 2016-08-12
EP3827823A1 (en) 2021-06-02
IL239490A0 (en) 2015-08-31
KR101891144B1 (ko) 2018-08-23
US11058677B2 (en) 2021-07-13
EA201591180A1 (ru) 2015-12-30
US20150320737A1 (en) 2015-11-12
HUE052299T2 (hu) 2021-04-28
CA2894170A1 (en) 2014-06-26
BR112015014367A2 (pt) 2017-07-11
AU2013361579A1 (en) 2015-06-18
AU2013361579B2 (en) 2018-05-24
EP2934510A1 (en) 2015-10-28
ZA201504404B (en) 2020-01-29
JP6373867B2 (ja) 2018-08-15
NZ708821A (en) 2020-03-27
PL2934510T3 (pl) 2021-07-05
IL239490B (en) 2018-12-31
MX2015007540A (es) 2016-04-13
EA201791321A1 (ru) 2018-04-30
MX368876B (es) 2019-10-21
CA2894170C (en) 2021-08-10
SI2934510T1 (sl) 2021-02-26
JP2016503058A (ja) 2016-02-01
DK2934510T3 (da) 2021-01-25
MX391620B (es) 2025-03-19
HK1214536A1 (zh) 2016-07-29
EP2934510B1 (en) 2020-10-28
PT2934510T (pt) 2021-01-13
CN104955453B (zh) 2018-09-18
WO2014100135A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
US20220000859A1 (en) Lfa-1 inhibitor formulations
US11717510B2 (en) Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
JP6527341B2 (ja) ポビドンヨード、眼科用組成物のための新規代替保存剤
US12350366B2 (en) Aqueous ophthalmic solutions of phentolamine and medical uses thereof
US9561280B2 (en) Aqueous liquid bromfenac composition having preservative efficacy
US11331311B2 (en) Prophylactic and/or therapeutic agent containing pyridylaminoacetic acid compound
HK1214536B (zh) Lfa-1抑制剂制剂
HK1214963B (en) Lfa-1 inhibitor formulations
EP3730137A1 (en) Therapeutic agent for glaucoma comprising fp agonist and blocker

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment